Table 1.
Pembrolizumab demographics for 2017–2023.
| n (%) | Cardiac Failure | Atrial Fibrillation | Myocardial Infarction | Pericardial Disease | Myocarditis | QT Prolongation | |
|---|---|---|---|---|---|---|---|
| Sex | Female | 52 (32.70) | 39 (35.14) | 23 (23.96) | 80 (43.48) | 107 (38.77) | 0 (0.00) |
| Male | 101 (63.52) | 68 (61.26) | 69 (71.88) | 104 (56.52) | 158 (57.25) | 0 (0.00) | |
| N/A | 5 (3.14) | 4 (3.60) | 4 (4.17) | 0 (0.00) | 11 (3.99) | 0 (0.00) | |
| Age | 71.62 ± 9.69 (N/A 37) |
71.58 ± 8.05 (N/A 24) |
70.00 ± 10.55 (N/A 45) |
63.80 ± 13.22 (N/A 43) |
69.59 ± 11.55 (N/A 41) |
0.00 ± 0.00 | |
| Reaction | Serious | 158 | 111 | 96 | 184 | 276 | 0 |
| Non-serious | 0 | 0 | 0 | 0 | 0 | 0 | |
| Outcome | Died | 67 (42.14) | 27 (24.32) | 45 (46.88) | 32 (17.39) | 112 (40.58) | 0 (0.00) |
| Life-threatening | 16 (10.06) | 15 (13.51) | 9 (9.38) | 20 (10.87) | 57 (20.65) | 0 (0.00) | |
| Hospitalized | 45 (28.30) | 35 (31.53) | 27 (28.13) | 76 (41.30) | 68 (24.64) | 0 (0.00) | |
| Disabled | 0 (0.00) | 0 (0.00) | 0 (0.0) | 0 (0.0) | 1(0.36) | 0 (0.00) | |
| Other | 30 (18.87) | 34 (30.63) | 15 (15.63) | 56 (30.43) | 38 (13.77) | 0 (0.00) |